An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Trial Profile

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs PRN 1008 (Primary)
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Believe-PV
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 21 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2019.
    • 18 Sep 2017 The data from this trial (n=12) were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress 2017, as reported in a Principia Biopharma Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top